Biotech News

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Atea (AVIR)Atea2026-05-12 20:06 ESTEarnings

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to Complete Enrollment Mid-2026; Topline Results Expected Around Year-End 2026

Related news

AVIRAtea2026-05-05 11:00 EST

Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026

AVIRAtea2026-08-12 20:05 EST

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

ENTAEnanta Pharmaceuticals2026-02-09 21:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025

ENTAEnanta Pharmaceuticals2026-08-10 20:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

COCPCocrystal Pharma2026-05-15 12:00 EST

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

ABUSArbutus2026-05-13 11:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

IMNNImunon2026-05-12 12:00 EST

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ASMBAssembly Biosciences2026-05-07 20:00 EST

Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

ANTXAN2 Therapeutics2026-08-11 20:00 EST

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

View all latest news

Atea

Oral Antiviral Therapeutics Atea Pharmaceuticals develops oral antiviral therapies for serious viral diseases. Its pipeline is built around nucleotide and nucleoside analog chemistry and combination treatment strategies. Bemnifosbuvir and Ruzasvir The lead regimen combines the nucleotide polymerase inhibitor bemnifosbuvir with the NS5A...

Recent company news

AVIRAtea2026-09-08 11:00 EST

Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

AVIRAtea2026-08-12 20:05 EST

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

AVIRAtea2026-08-05 11:00 EST

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

AVIRAtea2026-07-28 11:00 EST

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

AVIRAtea2026-07-14 11:00 EST

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

Stock data

Close: 5.26 USD
Market cap: 341.72M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States